Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium’s Dosing Regimens in Multiple Sclerosis

December 15, 2023

https://www.prnewswire.com/news-releases/immunic-receives-notice-of-allowance-for-united-states-patent-protecting-vidofludimus-calciums-dosing-regimens-in-multiple-sclerosis-301994301.html

– Fundamental New Patent Covers Treatment of Multiple Sclerosis Into 2038 and Beyond –

– Third U.S. Patent Directed to Use of Vidofludimus Calcium in Multiple Sclerosis –

Read more at prnewswire.com

Related news for (IMUX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.